The Patent Finder

Oryzon Genomics, S.A.

Also on record
Records under this name other than the patents Oryzon Genomics, S.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 24 patents it holds.

Showing 1 to 10 of 10 · Back to Oryzon Genomics, S.A.

PatentTitleStatus Expires Confidence
US 9,790,196Lysine demethylase inhibitors for diseases and disorders associated with Flaviviridae
Lapsed on the fee record
Ended Oct 17, 2025 · From the USPTO record
Lapsed on the fee recordEnded Oct 17, 2025From the USPTO record
US 9,676,701Cyclopropylamine derivatives useful as LSD1 inhibitors
Lapsed on the fee record
Ended Jun 13, 2025 · From the USPTO record
Lapsed on the fee recordEnded Jun 13, 2025From the USPTO record
US 9,616,058Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
Lapsed on the fee record
Ended Apr 11, 2025 · From the USPTO record
Lapsed on the fee recordEnded Apr 11, 2025From the USPTO record
US 9,186,337Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
Lapsed on the fee record
Ended Nov 17, 2023 · From the USPTO record
Lapsed on the fee recordEnded Nov 17, 2023From the USPTO record
US 9,061,966Cyclopropylamine inhibitors of oxidases
Lapsed on the fee record
Ended Jun 23, 2023 · From the USPTO record
Lapsed on the fee recordEnded Jun 23, 2023From the USPTO record
US 9,006,449Cyclopropylamine derivatives useful as LSD1 inhibitors
Lapsed on the fee record
Ended Apr 14, 2023 · From the USPTO record
Lapsed on the fee recordEnded Apr 14, 2023From the USPTO record
US 10,214,477(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
Lapsed on the fee record
Ended Feb 26, 2023 · From the USPTO record
Lapsed on the fee recordEnded Feb 26, 2023From the USPTO record
US 8,946,296Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
Lapsed on the fee record
Ended Feb 3, 2023 · From the USPTO record
Lapsed on the fee recordEnded Feb 3, 2023From the USPTO record
US 8,859,555Lysine Specific Demethylase-1 inhibitors and their use
Lapsed on the fee record
Ended Oct 14, 2022 · From the USPTO record
Lapsed on the fee recordEnded Oct 14, 2022From the USPTO record
US 7,745,127Molecular diagnostic method for dementia with lewy bodies
Lapsed on the fee record
Ended Jun 29, 2014 · From the USPTO record
Lapsed on the fee recordEnded Jun 29, 2014From the USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited